Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Receivables (2019 - 2025)

Inmune Bio (INMB) has disclosed Receivables for 7 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 222.29% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 222.29% year-over-year, with the annual reading at $4.5 million for FY2025, 45.17% up from the prior year.
  • Receivables hit $4.5 million in Q4 2025 for Inmune Bio, up from $2.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.5 million in Q4 2025 to a low of $100000.0 in Q1 2021.
  • Historically, Receivables has averaged $1.4 million across 5 years, with a median of $1.4 million in 2024.
  • Biggest five-year swings in Receivables: crashed 96.55% in 2021 and later soared 222.29% in 2025.
  • Year by year, Receivables stood at $400000.0 in 2021, then plummeted by 75.0% to $100000.0 in 2022, then skyrocketed by 2342.0% to $2.4 million in 2023, then crashed by 42.3% to $1.4 million in 2024, then skyrocketed by 222.29% to $4.5 million in 2025.
  • Business Quant data shows Receivables for INMB at $4.5 million in Q4 2025, $2.5 million in Q3 2025, and $2.6 million in Q2 2025.